Mirum Pharmaceuticals MIRM
$ 41.86
1.76%
Quarterly report 2024-Q3
added 11-12-2024
Mirum Pharmaceuticals Balance Sheet 2011-2024 | MIRM
Annual Balance Sheet Mirum Pharmaceuticals
2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-285 M | -25.8 M | -28.7 M | -137 M | -8.32 M | -52 M | - | - | - | - | - | - | - |
Long Term Debt |
617 K | 1.26 M | 1.9 M | 2.63 M | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
1.1 M | 931 K | 711 K | 636 K | 397 K | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | 50.3 M | 3.29 M | 59.8 M | - | - | - | - | - | - | - |
Total Current Liabilities |
87.1 M | 64.7 M | 42.6 M | 18.5 M | 13.1 M | - | - | - | - | - | - | - | - |
Total Liabilities |
398 M | 211 M | 174 M | 68.8 M | 16.4 M | 62.3 M | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-556 M | -393 M | -257 M | -173 M | -69.9 M | -17.3 M | - | - | - | - | - | - | - |
Total Assets |
647 M | 353 M | 295 M | 241 M | 147 M | 52 M | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
286 M | 28 M | 31.3 M | 142 M | 12 M | - | - | - | - | - | - | - | - |
Book Value |
249 M | 142 M | 120 M | 172 M | 130 M | -10.3 M | - | - | - | - | - | - | - |
Total Shareholders Equity |
249 M | 142 M | 120 M | 172 M | 130 M | -17.3 M | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Mirum Pharmaceuticals
2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
8.48 M | 8.24 M | 328 K | 617 K | 868 K | 1.15 M | 1.06 M | 1.26 M | 1.31 M | - | 1.71 M | 1.9 M | 2.09 M | 2.27 M | 2.45 M | 2.63 M | 2.63 M | 2.63 M | 2.63 M | 3.25 M | 3.25 M | 3.25 M | 3.25 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
436 M | 432 M | 417 M | 398 M | 382 M | 365 M | 192 M | 211 M | 195 M | - | 169 M | 174 M | 179 M | 152 M | 88.4 M | 68.8 M | 68.8 M | 68.8 M | 68.8 M | 16.4 M | 16.4 M | 16.4 M | 16.4 M | 2.45 M | 2.45 M | 2.45 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-620 M | -606 M | -582 M | -556 M | -521 M | -497 M | -423 M | -393 M | -356 M | - | -294 M | -257 M | -315 M | -268 M | -224 M | -173 M | -173 M | -173 M | -173 M | -69.9 M | -69.9 M | -69.9 M | -69.9 M | -17.3 M | -17.3 M | -17.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
668 M | 661 M | 652 M | 647 M | 651 M | 444 M | 334 M | 353 M | 364 M | - | 278 M | 295 M | 235 M | 248 M | 222 M | 241 M | 241 M | 241 M | 241 M | 147 M | 147 M | 147 M | 147 M | 52 M | 52 M | 52 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
223 M | 233 M | 303 M | 286 M | 303 M | 297 M | 49.4 M | 28 M | 35.8 M | - | 46.3 M | 31.3 M | 55.8 M | 91.9 M | 90.7 M | 142 M | 142 M | 142 M | 142 M | 12 M | 12 M | 12 M | 12 M | 52 M | 52 M | 52 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
232 M | 229 M | 235 M | 249 M | 269 M | 78.6 M | 141 M | 142 M | 169 M | - | 109 M | 120 M | 56.4 M | 95.7 M | 134 M | 172 M | 172 M | 172 M | 172 M | 130 M | 130 M | 130 M | 130 M | 49.5 M | 49.5 M | 49.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
232 M | 229 M | 235 M | 249 M | 269 M | 78.6 M | 141 M | 142 M | 169 M | 111 M | 109 M | 120 M | 56.4 M | 95.7 M | 134 M | 172 M | 172 M | 172 M | 172 M | 130 M | 130 M | 130 M | 130 M | -17.3 M | -17.3 M | -17.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency